BioSpace News Archive

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that initial clinical data from the Phase 1 portion of its Phase 1/2 monotherapy trial of ZN-c3, the Company’s WEE1 inhibitor, in advanced solid tumors has been selected for presentation at the upcoming virtual American Association for Cancer Research

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually from March 9-10, 2021. The company will also host one-on-one meetings with attendees. A live audio webcast of the presentation will be available o

Global health service company Cigna Corporation announced that Brian Evanko, executive vice president and chief financial officer, will present at the Barclays Global Healthcare Conference, Mar. 10, 2021, through a virtual webcast.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber .

Delivering on commitments announced in 2020, BMS donates funds to 56 nonprofits serving medically underserved populations across the U.S.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 - 10, 2021.

-- Record Fourth-Quarter 2020 Net Sales of $745.3 Million Increased 105 Percent; Fourth-Quarter 2020 GAAP Net Income of $190.6 Million; Adjusted EBITDA of $371.0 Million --

Fourth-Quarter 2020 Results and Highlights: Consolidated revenue increased 18% to $126 million Clinical Services revenue increased 14% to $107 million Pharma Services revenue increased 43% to $19 million

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that John Beaver , President and Chief Executive Officer, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright Global Life Sciences Investor Conference